Source: Eur Respir J 2016; 47:1318-1320
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Price Laura C., Devaraj Anand, Wort S. John. Central pulmonary arteries in idiopathic pulmonary fibrosis: size really matters. Eur Respir J 2016; 47:1318-1320

Member's Comments

No comment yet.

Related content which might interest you: The contributing factors to mean pulmonary artery pressure in idiopathic pulmonary fibrosis Source: International Congress 2016 – Latest insights into chronic care Year: 2016 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 47:1445-1451 Year: 2016 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Right ventricular REMODELING in idiopathic pulmonary fibrosis with or without pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Morphometric characteristic of pulmonary artery in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis Source: Eur Respir J 2016; 47: 673-676 Year: 2016 Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 Pulmonary hypertension in idiopathic pulmonary fibrosis: Utility of HRCT Source: International Congress 2014 – COPD and PAH related imaging Year: 2014 Pulmonary hypertension in idiopathic pulmonary fibrosis: correlation to pulmonary function and exercise parameters Source: Eur Respir J 2007; 30: Suppl. 51, 607s Year: 2007 Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Source: Eur Respir J 2007; 30: 715-721 Year: 2007 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Right ventricular dysfunction in pulmonary hypertension with combined pulmonary fibrosis and emphysema syndrome Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Pulmonary artery diameter but not diameter ratio is indicative of pulmonary hypertension in systemic sclerosis Source: International Congress 2015 – A more functional view of chest pathology Year: 2015